15th Apr 2005 15:30
PRODUCT DEVELOPMENT UPDATE SESSION - May 10thBasingstoke, UK and Philadelphia, US - April 15, 2005 - Shire PharmaceuticalsGroup plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) will host a product developmentupdate teleconference on Tuesday, May 10, 2005 beginning at 14:00 BST/09:00EST.Live conference call:Eliseo Salinas, Chief Scientific Officer and Greg Flexter, Executive VicePresident and General Manager, North America, will host the call. Thepresentation will focus on three key Shire development candidates: MTS (ADHD),SPD503 (ADHD) and SPD476 (ulcerative colitis).Please RSVP via:Souheil Salah [email protected] (T: +44 (0)1256 894 160)Heidi Wunder [email protected] (T: +1 484 595 8709)The details of the live conference call are as follows:UK dial in +44 (0) 1452 568 061 US / Canada dial in +1 866 224 2972 Password Shire Live Webcast:The call will also be available live over the Internet via audio webcast,accessible through www.shire.com in the Investor Relations section. A slidepresentation to accompany the call will also be available on the Shire website.Replay:A replay of the presentation will be available for two week. Details are asfollows:UK dial in +44 0845 245 5205 US dial in +1 8662474222 Stnd Int Dial In Number +44 (0) 1452 550 000 Pin code 5617240# Webcast Replay www.shire.com, in the investor relations section If you have any problems accessing this, please contact: Souheil Salah on: +44(0) 1256 894160 or Heidi Wunder on: +1 484 595 8709For further information please contact:Investor Relations Souheil Salah (Rest of the World) +44 1256 894 160 Heidi Wunder (North America) +1 484 595 8252 Notes to editorsShire Pharmaceuticals Group plcShire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceuticalcompany with a strategic focus on meeting the needs of the specialist physicianand currently focuses on developing projects and marketing products in theareas of central nervous system (CNS), gastrointestinal (GI), and renaldiseases. Shire has operations in the world's key pharmaceutical markets (US,Canada, UK, France, Italy, Spain and Germany) as well as a specialist drugdelivery unit in the US.For further information on Shire, please visit the Company's website: www.shire.com."SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF1995Statements included herein that are not historical facts are forward-lookingstatements. Such forward-looking statements involve a number of risks anduncertainties and are subject to change at any time. In the event such risks oruncertainties materialize, Shire's results could be materially affected. Therisks and uncertainties include, but are not limited to, risks associated withthe inherent uncertainty of pharmaceutical research, product development,manufacturing and commercialization, the impact of competitive products,including, but not limited to, the impact of those on Shire's Attention Deficit& Hyperactivity Disorder (ADHD) franchise, patents, including but not limitedto, legal challenges relating to Shire's ADHD franchise, government regulationand approval, including but not limited to Health Canada's suspension ofADDERALL XR sales in Canada and the expected product approval dates ofMETHYPATCH‚® (MTS) (ADHD), SPD503 (ADHD), SPD465 (ADHD), SPD476 (ulcerativecolitis), SPD 480 (ulcerative colitis) and NRP104 (ADHD), including itsscheduling classification by the Drug Enforcement Agency in the United States,Shire's ability to secure new products for development and other risks anduncertainties detailed from time to time in Shire's filings with the Securitiesand Exchange Commission, including its Annual Report on Form 10-K for the yearended December 31, 2004Page 2 of 2Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release Registered in England 2883758 Registered Office as aboveENDShire Pharmaceuticals Group PLCRelated Shares:
Shire